IP Library Granted Patent US 12,285,347
Granted Patent B2
US 12,285,347 · App. 17/393,120 · Granted Apr 29, 2025

Intracranial stent for insertion into the cerebral venous sinus system and methods of use

Inventor: Athos Patsalides (New York, NY)
Assignee: Sonorous NV
A61F2/966A61F2/90A61F2002/9528A61F2002/9534A61F2240/002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,285,347
App. No.
17/393,120
Granted
Apr 29, 2025
Kind
B2
Abstract

A stent for insertion into an intracranial blood vessel of the cerebral venous sinus system includes a proximal end, a distal end, a body between the proximal end and the distal end, the body comprising a plurality of wires in a closed pattern, wherein the stent is configured for insertion into an intracranial blood vessel of the cerebral venous sinus system. The stent is further capable of being repositioned, retrieved/re-sheathed, and removed for more precise delivery.

Claims (25)

1. A stent for permanent implantation into a cerebral venous sinus having a stenosis, comprising:

a proximal end, a distal end, and

a tubular flexible body of braided wire providing a closed cell pattern having a variable cell size, between the proximal end and the distal end, wherein the tubular flexible body has the same diameter at the proximal end and the distal end of the stent, and a length of between about 60 mm and about 80 mm; wherein the stent is configured for insertion and permanent implantation into a cerebral venous sinus, the stent being constrained within a lumen of a delivery catheter until the stent is positioned and deployed in the cerebral venous sinus wherein the stent self-expands to open the stenosis after being deployed, and wherein the stent has customized, variable zones of chronic outward force and is configured to secure itself to the surrounding venous sinus walls to be retrievable or re-sheathable, and to be permanently implanted in a desired location in the cerebral venous sinus.

2. The stent of claim 1 , wherein the stent is configured to be repositionable in the cerebral venous sinus after deployment.

3. The stent of claim 1 , wherein the stent can be retrieved after it has begun to expand.

4. The stent of claim 1 , wherein the stent can be re-sheathed within the lumen of the delivery catheter after the stent has begun to expand.

5. The stent of claim 1 , wherein the stent is capable of transitioning between a collapsed configuration and an expanded configuration.

6. The stent of claim 1 , wherein the cerebral venous sinus is selected from the group consisting of the superior sagittal venous sinus, the transverse venous sinus, the sigmoid venous sinus, and the straight venous sinus.

7. The stent of claim 1 , wherein the stent is used to treat a medical condition selected from the group consisting of idiopathic intracranial hypertension, pulsatile tinnitus, cerebral venous insufficiency, intracranial venous thrombosis, and intracranial venous stenosis.

8. The stent of claim 7 , wherein intracranial venous stenosis comprises a medical condition resulting from compression from tumor, compression from brain parenchyma, compression from arachnoid granulation, or thrombus.

9. The stent of claim 7 , wherein the medical condition is pulsatile tinnitus.

10. The stent of claim 1 , wherein the stent can have customized, variable cell size to adapt to a non-cylindrical shape of the cerebral venous sinus.

11. The stent of claim 1 , wherein the stent can have customized, variable cell size to prevent obstruction of flow from a tributary vein into the cerebral venous sinus.

12. The stent of claim 1 , wherein the stent further comprises a coating of one or more therapeutic agents.

13. The stent of claim 1 wherein the stent is formed of struts having a diameter adjusted to provide radial stiffness in a deployed condition to enable apposition to a vessel wall.

14. The stent of claim 13 wherein the stent is capable of being retrieved or re-sheathed even when the stent is between about seventy and eighty-five percent expanded.

15. An intracranial implant delivery system for implanting a stent into a cerebral venous sinus, comprising:

a catheter comprising a distal end, a proximal end, and a lumen extending between the distal end and the proximal end;

a tip located at the distal end of the catheter; and a stent comprising:

a proximal end, a distal end, and

a tubular flexible body of braided wire, providing a closed cell pattern and variable cell size, between the proximal end and the distal end of the stent wherein the tubular flexible body has the same diameter of between about 6 mm and 10 mm at the proximal end and the distal end of the stent, and a length of between about 60 mm and about 80 mm and wherein the stent has customized, variable zones of chronic outward force and is configured for insertion into a cerebral venous sinus to alleviate a stenosis, the stent being constrained within a lumen of a delivery catheter until the stent is positioned and deployed in the cerebral venous sinus, and wherein the stent is configured to be re-sheathable, to expand after deployment, to alleviate a stenosis in the venous sinus by forcing a narrowed segment of the vein to expand, and to secure itself to surrounding venous sinus walls and to be implanted in a desired location in the cerebral venous sinus.

16. The system of claim 15 , wherein the stent can have customized, variable zones of chronic outward force that mimic the compliance and adapt to the anatomy of the cerebral venous sinus.

17. The system of claim 15 , wherein the stent can have customized, variable cell size to adapt to a non-cylindrical shape of the cerebral venous sinus.

18. The system of claim 15 , wherein the stent can have customized, variable cell size to prevent obstruction of flow from a tributary vein into the cerebral venous sinus.

19. The system of claim 15 , wherein the stent further comprises a coating of one or more therapeutic agents.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2025
From: PATSALIDES, ATHOS
To: SONOROUS NV
Reel/Frame 070725/0668 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2023
From: PATSALIDES, ATHOS
To: SONOROUS NV
Reel/Frame 066059/0499 →
Continuity (2)
Provisional Application 63060218 · Aug 3, 2020
Related Publication 20220031488A1 · Feb 3, 2022
References Cited (104)
US 7326225B2 · Ferrera et al. · 2008 [cited by applicant]
US 7645275B2 · O'Connor et al. · 2010 [cited by applicant]
US 8066757B2 · Ferrera et al. · 2011 [cited by applicant]
US 8070791B2 · Ferrera et al. · 2011 [cited by applicant]
US 8088140B2 · Ferrera et al. · 2012 [cited by applicant]
US 8197493B2 · Ferrera et al. · 2012 [cited by applicant]
US 8545514B2 · Ferrera · 2013 [cited by applicant]
US 8572262B2 · Ensing et al. · 2013 [cited by applicant]
US 8574262B2 · Ferrera et al. · 2013 [cited by applicant]
US 8585713B2 · Ferrera et al. · 2013 [cited by applicant]
US 8945143B2 · Ferrera et al. · 2015 [cited by applicant]
US 8945172B2 · Ferrera et al. · 2015 [cited by applicant]
US 8998985B2 · Gross et al. · 2015 [cited by applicant]
US 9198687B2 · Fulkerson et al. · 2015 [cited by applicant]
US 9220522B2 · Fulkerson et al. · 2015 [cited by applicant]
US 9320532B2 · Ferrera et al. · 2016 [cited by applicant]
US 9387098B2 · Ferrera et al. · 2016 [cited by applicant]
US 9439791B2 · Vong et al. · 2016 [cited by applicant]
US 9566071B2 · Takahashi et al. · 2017 [cited by applicant]
US 9566072B2 · Le et al. · 2017 [cited by applicant]
US 9585741B2 · Ma · 2017 [cited by applicant]
US 9775730B1 · Walzman · 2017 [cited by examiner]
US 9808359B2 · Ferrera et al. · 2017 [cited by applicant]
US 9926680B2 · Boasso · 2018 [cited by applicant]
US 10016211B2 · Ferrera et al. · 2018 [cited by applicant]
US 10070878B2 · Ma · 2018 [cited by applicant]
US 10123803B2 · Ferrera et al. · 2018 [cited by applicant]
US 10143310B1 · Wang · 2018 [cited by applicant]
US 10182931B2 · Pung et al. · 2019 [cited by applicant]
US 10322020B2 · Lam et al. · 2019 [cited by applicant]
US 10335299B2 · Lam et al. · 2019 [cited by applicant]
US 10342546B2 · Sepetka et al. · 2019 [cited by applicant]
US 10383751B2 · Ferrera et al. · 2019 [cited by applicant]
US 10398877B2 · Vitullo et al. · 2019 [cited by applicant]
US 10617544B2 · Sepetka et al. · 2020 [cited by applicant]
US 10722242B2 · Le et al. · 2020 [cited by applicant]
US 10729447B2 · Shimizu et al. · 2020 [cited by applicant]
US 20020032459A1 · Horzewski et al. · 2002 [cited by applicant]
US 20090132024A1 · Berkhoff · 2009 [cited by applicant]
US 20100174366A1 · Avior · 2010 [cited by applicant]
US 20110160763A1 · Ferrera et al. · 2011 [cited by applicant]
US 20110301685A1 · Kao · 2011 [cited by applicant]
US 20110319917A1 · Ferrera et al. · 2011 [cited by applicant]
US 20120022576A1 · Ferrera et al. · 2012 [cited by applicant]
US 20120197285A1 · Martin et al. · 2012 [cited by applicant]
US 20130030521A1 · Nitzan et al. · 2013 [cited by applicant]
US 20130304193A1 · Osman · 2013 [cited by examiner]
US 20140058436A1 · Rosenbluth et al. · 2014 [cited by applicant]
US 20140243882A1 · Ma · 2014 [cited by applicant]
US 20140309673A1 · Dacuycuy et al. · 2014 [cited by applicant]
US 20160206323A1 · Hebert et al. · 2016 [cited by applicant]
US 20160206452A1 · Berez et al. · 2016 [cited by applicant]
US 20160256255A9 · Ma · 2016 [cited by applicant]
US 20160354099A1 · Turjman et al. · 2016 [cited by applicant]
US 20170086992A1 · Ferrera et al. · 2017 [cited by applicant]
US 20170196717A1 · Fulkerson et al. · 2017 [cited by applicant]
US 20180250498A1 · Stern et al. · 2018 [cited by applicant]
US 20180256378A1 · Callister · 2018 [cited by examiner]
US 20180339148A1 · Kong · 2018 [cited by applicant]
US 20190231302A1 · Tieu · 2019 [cited by applicant]
US 20190298977A1 · Heilman et al. · 2019 [cited by applicant]
US 20190364374A1 · Jensen et al. · 2019 [cited by applicant]
US 20200021929A1 · Farrar-Ganes et al. · 2020 [cited by applicant]
US 20200069410A1 · Amans · 2020 [cited by applicant]
US 20200146852A1 · Raychev et al. · 2020 [cited by applicant]
US 20200368388A1 · You · 2020 [cited by examiner]
US 20210100667A1 · Ngo et al. · 2021 [cited by applicant]
US 20210137715A1 · Ringwala et al. · 2021 [cited by applicant]
US 20210205105A1 · Stout · 2021 [cited by applicant]
US 20220096792A1 · Bednarek · 2022 [cited by applicant]
US 20220226136A1 · Stout · 2022 [cited by applicant]
US 20220409239A1 · Fischell et al. · 2022 [cited by applicant]
US 20230097980A1 · Amans · 2023 [cited by examiner]
US 20230293283A1 · Takahashi et al. · 2023 [cited by applicant]
US 20240074879A1 · Ferrera et al. · 2024 [cited by applicant]
US 20240139471A1 · Kessler et al. · 2024 [cited by applicant]
US 20240164927A1 · Stout · 2024 [cited by applicant]
US 20240268976A1 · Amans et al. · 2024 [cited by applicant]
US 20240366360A9 · Takahashi et al. · 2024 [cited by applicant]
EP 1486186 · 2004 [cited by applicant]
WO WO2014150288A2 · 2014 [cited by applicant]
WO WO2019135220 · 2019 [cited by applicant]
WO WO2020109979 · 2020 [cited by applicant]
WO WO2022031730 · 2022 [cited by applicant]
WO WO2022165166 · 2022 [cited by applicant]
WO WO2023220571A1 · 2023 [cited by applicant]
PCT International Search Report and Written Opinion dated Nov. 18, 2021, International Application No. PCT/US2021/044382, pp. 1-8. [cited by applicant]
Srikanth R. Boddu et al., “Anatomic measurements of cerebral venous sinuses in idiopathic intrascranial hypertension patients,” PLoS One 13(6): 2018, pp. 1-10. [cited by applicant]
B. Schaller, “Physiology of cerebral venous blood flow: from experimental data in animals to normal function in humans,” Brain Research Reviews, 46 (2004), pp. 243-260. [cited by applicant]
Boddu et al., “Resolution of Pulsatile Tinnitus after Venous Sinus Stenting in Patients with Idiopathic Intracranial Hypertension,” PLoS One, Oct. 2016, 11(10): e0164466, 13 pages. [cited by applicant]
Bosstent System Product, Novel Neuro Interventional BosStent System, 17 pages. [cited by applicant]
Haley et al., A Rational Approach to Meshing Cerebral Venous Geometries for High-Fidelity Computational Fluid Dynamics, 24 pages. [cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2021/044382, mailed on Feb. 16, 2023, 8 pages. [cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2022/014297, mailed on May 18, 2022, 10 pages. [cited by applicant]
Mayo Foundation for Medical Education and Research (MFMER), “Tinnitus symptoms & causes,” Mayo Clinic, Mar. 5, 2019, 1998-2020 , CON-20118272, 8 pages. [cited by applicant]
Mayo Foundation for Medical Education and Research, “Tinnitus diagnosis & treatment,” Mayo Clinic, available on or before Jun. 14, 2019, via Internet Archive: Wayback Machine URL <https://www.mayoclinic.org/diseases-con… [cited by applicant]
Park et al., “Awake embolization of sigmoid sinus diverticulum causing pulsatile tinnitus: simultaneous confirmative diagnosis and treatment,” Interventional Neuroradiology, Oct. 2011, 17:376-379. [cited by applicant]
The Pulse Clinic: Advanced Pulsatile Tinnitus & Intracranial Hypertension Assessment; 36 pages. [cited by applicant]
Venous Stenting Landscape, 22 pages. [cited by applicant]
fwmetals.com [online], “Composite Materials: DFT® wire,” retrieved on Apr. 22, 2024, retrieved from URL<https://www.fwmetals.com/products/composites-dft-wire/dft-wire/>, 1 page. [cited by applicant]
steegerusa.com [online], “Catheter Braid Patterns for Medical Braiding,” retrieved on Apr. 22, 2024, retrieved from URL<https://steegerusa.com/typical-braid-patterns-for-medical-braiding/#:˜:text=Braid%20density%2C%20al… [cited by applicant]
Sundararajan et al., “Dural Venous Sinus Stenosis: Why Distinguishing Intrinsic-versus-Extrinsic Stenosis Matters,” AJNR Am J Neuroradiol, Feb. 2021, available online Jan. 7, 2021, 42(2):288-296. [cited by applicant]
Extended European Search Report in European Appln. No. 21854427.8, mailed on Jul. 30, 2024, 8 pages. [cited by applicant]
Office Action in European Appln. No. 21854427.8, mailed on Feb. 14, 2025, 6 pages. [cited by applicant]